Apmonia Therapeutics is a biotechnology company developing a pipeline of therapies for various forms of cancer, based on specific and selective targeting of the tumor microenvironment.
Amount sought: $20 million (more than $16 million already secured)
Current series: Series A
Startup contact: a.jeanne@apmonia-therapeutics.com
Theme: Health - Therapeutics
Applications: Therapeutic Development
Partnerships and awards: Winner of the i-Lab competition, i-Nov EIC Accelerator 2024
Laboratory: MeDyc
Institutions: URCA
Intellectual property: 4 patent families
Technology
Apmonia Tx offers breakthrough technology in the field of cancer targeting, attacking extracellular matrix proteins as a new therapeutic class. At the convergence of several scientific and technological advances, Apmonia Tx is developing both a unique in silico discovery platform [powered by virtual screening and AI] and a portfolio of drug candidates.
Applications
Therapeutic solutions for solid tumors that are refractory to available treatments (high relapse rate and/or lack of targeted therapies), including orphan tumor pathologies with high unmet medical needs.
Benefits
Comprehensive modulation of the tumor microenvironment, specificity, and favorable safety profiles. Controlled production.
Maturity
Phase 1
For more information
Contact your dedicated advisor